GSK to spend $1 bn to raise stake in Indian drugmaker GlaxoSmithKline Pharmaceuticals Ltd
- Govt has decided to drop anti-piracy charges against Italian marines, Centre tells SC
- LIVE: Rahul takes a dig at Modi, says BJP thinks one man can run the country
- Rajiv Gandhi assassination case: SC to hear Centre's plea on restraining TN govt from releasing convicts
- Leopard on the loose in Meerut, officials order closure of schools and colleges
- Konan Poshpora: Probe official speaks up, says was threatened
GlaxoSmithKline Plc (GSK) said on Monday it plans to raise its stake in its Indian pharmaceutical unit to up to 75 per cent from 50.7 percent, through an open offer, in a deal worth about 629 million pounds ($1.02 billion).
GSK will buy up to 20.6 million shares of GlaxoSmithKline Pharmaceuticals Ltd at 3,100 rupees a share, a premium of 26 percent over its market price on Friday, the company said in a statement.
The British drugmaker said it plans to keep the Indian unit listed even after raising the stake.
As per Indian regulations, promoters of stock exchange-listed companies can hold up to a maximum of 75 percent stake. If the promoter shareholding rises beyond 75 percent, then the company has to be de-listed from the bourses.
In February, GSK lifted its stake in its publicly-listed Indian consumer healthcare subsidiary to 72.5 percent from 43.2 percent for $901 million, deepening its footprint in emerging markets and non-prescription products.
Shares in India's GlaxoSmithKline Pharmaceuticals Ltd surged 20 per cent in pre-open trading to its maximum daily limit.
- 4 more bodies found on Arunachal border, curfew in Assam town
- ‘Polls have come in the way of new norms for tech institutes’
- Food security Act also covers foreign nationals, refugees, says Law Ministry
- Lokayukta meets Bhardwaj over Bill
- Days before school admissions start, HC order on RTE creates confusion
- NGO seeks funds to train HIV+ patients